Aptevo Therapeutics (APVO) Stock
Aptevo Therapeutics Chart
Company Profile
Price: $2.38
Market Cap: $3.47M
Exchange: NASDAQ
CEO: Mr. Marvin L. White
Sector: Healthcare
Industry: Biotechnology
Employees: 37
Headquarters: Seattle, WA
Website: Aptevo Therapeutics
Business Summary
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics News
Aptevo to Participate in March Conferences
SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company is participating in two conferences in March, as follows: The 37th Annual Roth Conference March 16-18, 2025 in Dana Point, CA. Aptevo will participate in a fireside chat with covering analyst Jonathan Aschoff while onsite.
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Marvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with Aptevo Therapeutics' (Nasdaq:APVO) President and CEO Marvin White, will air on RedChip's Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, Saturday, February 15, at 7 p.m. Eastern Time (ET).
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable Disease Rate, in ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Makes the Case for Continued Development of First-in-Class Anti-Cancer Agent SEATTLE, WA / ACCESS Newswire / February 14, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the year ended December 31, 2024 and provided a business update. Business Update "2024 was a successful year for Aptevo, as we've demonstrated the power of our science and our commitment to advancing oncology care.
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today. Details Session Title: Bi and Multispecific Biologics Talk Title: Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform (talk being given as part of this session) Session Chair and Talk Presenter: Peter Pavlik, PhD Date/Time: Wednesday, January 15th from 3:15-5:20 US Pacific time.
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No.
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual disease (MRD)-negative status (100% elimination of cancer cells). The results build on data from the prior trial, in which 100% of frontline patients also achieved remission.
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced additional details about the Company's preclinical bispecific antibody, APVO442, differentiated to target prostate cancer with enhanced precision and minimized safety risk. APVO442 is the first molecule developed using Aptevo's cutting-edge ADAPTIR-FLEX platform, which is driving innovation in antibody engineering for complex disease management.
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-37 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on December [3], 2024 at 5:01 p.m.
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform" at Cambridge Healthcare Institute's, Pep Talk 2025 SEATTLE, WA / ACCESSWIRE / November 26, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, todayannounced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a "Bi and Multispecific Biologics" session and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform," at the Cambridge Healthcare Institute's, Pep Talk conference, in January 2025. The presentation will illustrate how Aptevo leverages its proprietary platforms to rapidly advance the development of innovative cancer therapies and use clinical candidates Mipletamig and ALG.APV-527 to exemplify proof of concept for its modular biotherapeutic approach, reducing risk and increasing the likelihood of clinical success for future drug candidates.
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA / ACCESSWIRE / November 22, 2024 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised to potentially address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. As bispecific antibodies gain prominence for their revolutionary therapeutic potential and expanding market opportunities, Aptevo's differentiated platforms (ADAPTIR® and ADAPTIR-FLEX®) and promising clinical results across two clinical programs (mipletamig and ALG.APV-527), together with preclinical assets (APVO711, APVO603 and APVO442) are demonstrating how bispecifics rationally differentiated for safety and targeted efficacy may impact the future of cancer care.
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved patient outcomes Favorable early safety, efficacy, tolerability and durability of remission data informed Aptevo's ongoing RAINIER Phase 1b/2 trial SEATTLE, WA / ACCESSWIRE / November 20, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today expanded on the potential of mipletamig, currently being evaluated as frontline therapy for the treatment of Acute Myeloid Leukemia (AML), in combination with standard of care venetoclax and azacitidine, noting the first patient dosed in the ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies. The Company's move to evaluate mipletamig as frontline combination therapy is informed by favorable data from earlier trials, which demonstrated strong safety, efficacy, and tolerability profiles, alongside evidence of durable remission.
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activation in the tumor microenvironment Data Presented at Society for Immunotherapy of Cancer on November 8, 2024 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / November 11, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced preliminary data from the companies' Phase 1 trial evaluating the first-in-class bispecific antibody, ALG.APV-527, as monotherapy for the treatment of multiple solid tumor types likely to express tumor antigen 5T4. These data indicate that trial endpoints of adequate exposure, safety, tolerability and biological activity were met.
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology Congress Additional Favorable Data to be Presented at the Society for Immunotherapy of Cancer Conference on November 8th Raises $5.75 Million in the Quarter SEATTLE, WA / ACCESSWIRE / November 7, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ending September 30, 2024 and provided a business update. Business Highlights Aptevo met multiple clinical milestones in the third quarter, including: Based on positive safety, tolerability efficacy and durability data in its completed dose escalation trial, Aptevo Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate the compound in combination with standard of care venetoclax + azacitidine in frontline patients with acute myeloid leukemia (AML).
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock (the "Common Warrants") at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / September 16, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock (the "Common Warrants") at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks* Outcomes also expected to identify recommended Phase 2 dose APVO436 renamed as mipletamig: Aptevo adopts new generic name for future use SEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today, announced initiation of the Company's Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts.
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. "After the successful completion of our APVO436 dose expansion trial, where we saw a 91% clinical benefit rate and an excellent safety, tolerability and duration of remission profile, we worked in the second quarter to finalize plans for the launch of the first part of our Phase 1b/2 trial, a dose optimization study, continuing evaluation of APVO436 in combination with venetoclax and azacitidine for the treatment of Acute Myeloid Leukemia (AML) in frontline patients.
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WA / ACCESSWIRE / June 28, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA. The conference is known for being the largest biotechnology industry conference of the year and is expected to attract more than 18,000 attendees from around the world.
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologies SEATTLE, WA / ACCESSWIRE / May 14, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced a presentation at The Essential Protein & Antibody Engineering Summit (PEGS) conference in Boston MA. The session, being offered today, Tuesday May 14, 2023 at 8:30 AM Eastern time and entitled "Development of Target Activated ADAPTIRs for Tumor Immunotherapy," will be led by Dr. Peter Pavlik, PhD, Senior Director of Protein Engineering at Aptevo and will focus on the strategic deployment of early functional screening of a diverse group of binding domains against a given target, combined with screening in multiple possible final formats to elicit varied functional activity, exemplified by preclinical and clinical data supporting predictive outcomes.
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new adverse events since the transition to the higher dose level APVO436 Phase 1b/2 dose optimization trial initiation of APVO436 for frontline AML in combination with venetoclax + azacitidine in venetoclax naïve patients expected 2Q 2024 SEATTLE, WA / ACCESSWIRE / May 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. A heavily pretreated breast cancer patient, enrolled in the ALG.APV-527 Phase 1 open-label, multi-center, multi-cohort trial for the treatment of multiple solid tumor types, entered the trial with progressive disease and improved to long-lasting stable disease (SD) while on therapy.
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common Warrant. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
Aptevo Therapeutics (NASDAQ: APVO ) stock is falling on Thursday after the clinical-stage biotechnology company priced a public offering for its shares. That public offering has Aptevo Therapeutics selling 3.4 million shares of APVO stock at a price of $1.35 each.
Aptevo Therapeutics Earnings
This section highlights Aptevo Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Aptevo Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $3.11M | $12.29M | $4.31M |
| Cost of Revenue | $- | $567.00K | $901.00K | $18.99M | $17.85M |
| Gross Profit | $- | $-567.00K | $2.21M | $-6.70M | $-13.54M |
| Gross Profit Ratio | 0.00% | 0.00% | 71.07% | -54.50% | -314.30% |
| Research and Development Expenses | $14.38M | $17.11M | $17.88M | $18.99M | $17.85M |
| General and Administrative Expenses | $10.22M | $11.77M | $13.87M | $14.70M | $13.95M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.22M | $11.77M | $13.87M | $14.70M | $13.95M |
| Other Expenses | $- | $- | $-1.53M | $-8.01M | $-1.32M |
| Operating Expenses | $24.60M | $28.88M | $31.75M | $33.69M | $31.80M |
| Cost and Expenses | $- | $28.88M | $31.75M | $33.69M | $31.80M |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $567.00K | $901.00K | $1.14M | $1.41M |
| EBITDA | $-24.60M | $-28.31M | $-27.74M | $-20.26M | $-26.09M |
| EBITDA Ratio | 0.00% | 0.00% | -2084.84% | -174.10% | -589.23% |
| Operating Income | $-24.60M | $-28.88M | $-28.64M | $-21.40M | $-27.49M |
| Operating Income Ratio | 0.00% | 0.00% | -919.75% | -174.10% | -638.06% |
| Total Other Income Expenses Net | $472.00K | $10.23M | $35.66M | $-8.01M | $-3.43M |
| Income Before Tax | $-24.13M | $-18.65M | $7.01M | $-29.41M | $-30.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 225.24% | -239.25% | -717.64% |
| Income Tax Expense | $- | $- | $-35.66M | $-2.10M | $-12.47M |
| Net Income | $-24.13M | $-17.41M | $42.67M | $-27.31M | $-18.45M |
| Net Income Ratio | 0.00% | 0.00% | 1370.23% | -222.20% | -428.13% |
| EPS | $-84.67 | $-62.62 | $69.25 | $-267.09 | $-416.37 |
| EPS Diluted | $-84.67 | $-62.62 | $69.21 | $-267.09 | $-416.37 |
| Weighted Average Shares Outstanding | 285.00K | 278.06K | 115.92K | 106.54K | 77.07K |
| Weighted Average Shares Outstanding Diluted | 285.00K | 278.06K | 115.97K | 106.54K | 77.07K |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $902.00K | $- | $- | $- | $-3.11M | $- | $- | $3.11M | $3.67M | $3.10M | $3.11M | $2.42M | $2.37M | $1.46M | $473.00K | $- |
| Cost of Revenue | $- | $- | $-106.00K | $106.00K | $116.00K | $123.00K | $150.00K | $178.00K | $161.00K | $222.00K | $3.87M | $242.00K | $4.54M | $4.37M | $4.72M | $5.36M | $4.91M | $4.49M | $4.44M | $4.01M |
| Gross Profit | $- | $- | $106.00K | $-106.00K | $786.00K | $-123.00K | $-150.00K | $-178.00K | $-3.27M | $-222.00K | $-3.87M | $2.87M | $-878.00K | $-1.27M | $-1.61M | $-2.94M | $-2.54M | $-3.03M | $-3.97M | $-4.01M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 87.10% | 0.00% | 0.00% | 0.00% | 105.20% | 0.00% | 0.00% | 92.20% | -24.00% | -41.10% | -51.80% | -121.50% | -107.00% | -207.18% | -838.69% | 0.00% |
| Research and Development Expenses | $3.88M | $3.10M | $3.75M | $3.65M | $3.48M | $3.89M | $5.46M | $4.17M | $4.67M | $4.48M | $3.87M | $4.87M | $4.54M | $4.37M | $4.72M | $5.36M | $4.91M | $4.49M | $4.44M | $4.01M |
| General and Administrative Expenses | $2.50M | $2.11M | $2.38M | $3.23M | $2.79M | $2.67M | $2.72M | $3.59M | $3.01M | $3.31M | $3.70M | $3.86M | $3.16M | $3.48M | $4.11M | $3.95M | $4.28M | $3.21M | $2.84M | $3.62M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.50M | $2.11M | $2.38M | $3.23M | $2.79M | $2.67M | $2.72M | $3.59M | $3.01M | $3.31M | $3.70M | $3.86M | $3.16M | $3.48M | $4.11M | $3.95M | $4.28M | $3.21M | $2.84M | $3.62M |
| Other Expenses | $- | $- | $-149.00K | $149.00K | $188.00K | $227.00K | $230.00K | $-67.00K | $2.52M | $-25.00K | $35.42M | $-2.26M | $-2.56M | $-2.33M | $-2.34M | $-782.00K | $-352.00K | $-702.00K | $4.00K | $-275.00K |
| Operating Expenses | $6.38M | $5.21M | $6.13M | $6.88M | $6.27M | $6.56M | $8.18M | $7.76M | $7.68M | $7.78M | $7.56M | $8.72M | $7.71M | $7.85M | $8.83M | $9.31M | $9.19M | $7.71M | $7.28M | $7.62M |
| Cost and Expenses | $6.38M | $5.21M | $-18.58M | $6.98M | $6.38M | $6.56M | $8.18M | $7.76M | $7.68M | $7.78M | $7.56M | $8.72M | $7.71M | $7.85M | $8.83M | $9.31M | $9.19M | $7.71M | $7.28M | $7.62M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $9.58M | $- | $- | $- | $- | $25.00K | $- | $2.26M | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $71.00K | $84.00K | $-261.00K | $106.00K | $116.00K | $123.00K | $150.00K | $178.00K | $161.00K | $222.00K | $276.00K | $242.00K | $260.00K | $296.00K | $299.00K | $289.00K | $342.00K | $300.00K | $309.00K | $455.00K |
| EBITDA | $-6.31M | $-5.13M | $-6.29M | $-6.88M | $-6.27M | $-6.44M | $-8.03M | $-7.58M | $-7.52M | $-7.56M | $-7.29M | $-5.37M | $-3.78M | $-4.46M | $-5.42M | $-6.59M | $-6.48M | $-5.95M | $-6.50M | $-7.17M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -694.90% | 0.00% | 0.00% | 0.00% | 241.59% | 0.00% | 0.00% | -172.41% | -103.14% | -143.86% | -174.37% | -272.57% | -272.95% | -406.43% | -1373.78% | 0.00% |
| Operating Income | $-6.38M | $-5.21M | $-6.02M | $-6.98M | $-6.38M | $-6.56M | $-8.18M | $-7.76M | $-7.68M | $-7.78M | $-7.56M | $-5.61M | $-4.04M | $-4.75M | $-5.72M | $-6.89M | $-6.82M | $-6.25M | $-7.28M | $-7.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -707.76% | 0.00% | 0.00% | 0.00% | 246.76% | 0.00% | 0.00% | -180.19% | -110.23% | -153.42% | -183.99% | -284.51% | -287.36% | -426.93% | -1539.11% | 0.00% |
| Total Other Income Expenses Net | $70.00K | $112.00K | $141.00K | $149.00K | $188.00K | $227.00K | $230.00K | $9.58M | $2.52M | $-25.00K | $35.42M | $-2.26M | $-2.56M | $-2.33M | $-2.34M | $-782.00K | $-352.00K | $-702.00K | $4.00K | $-2.38M |
| Income Before Tax | $-6.31M | $-5.10M | $-5.88M | $-6.83M | $-6.20M | $-6.33M | $-7.95M | $1.83M | $-5.16M | $-7.81M | $27.86M | $-7.88M | $-6.60M | $-7.08M | $-8.06M | $-7.67M | $-7.17M | $-6.95M | $-6.80M | $-10.00M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -686.92% | 0.00% | 0.00% | 0.00% | 165.80% | 0.00% | 0.00% | -252.89% | -180.00% | -228.59% | -259.29% | -316.81% | -302.19% | -474.91% | -1438.27% | 0.00% |
| Income Tax Expense | $- | $- | $-62.72K | $62.72K | $-293.00K | $162.59K | $27.91K | $-9.58M | $-35.52M | $-140.00K | $-149.00K | $2.09M | $626.00K | $-80.00K | $-132.00K | $-414.00K | $13.05M | $-157.00K | $- | $-10.79M |
| Net Income | $-6.31M | $-5.10M | $-5.88M | $-6.83M | $-5.90M | $-6.33M | $-7.95M | $11.41M | $30.35M | $-7.67M | $28.01M | $-9.96M | $-6.27M | $-7.00M | $-7.93M | $-7.26M | $-7.05M | $-6.79M | $-6.80M | $2.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -654.43% | 0.00% | 0.00% | 0.00% | -974.69% | 0.00% | 0.00% | -319.88% | -171.13% | -226.00% | -255.05% | -299.71% | -297.22% | -464.18% | -1438.27% | 0.00% |
| EPS | $-22.15 | $-17.89 | $-34.68 | $-9.95 | $-13.34 | $-22.16 | $-53.95 | $17.38 | $-31.59 | $-66.07 | $245.34 | $-68.59 | $-56.34 | $-62.93 | $-76.93 | $-72.26 | $-75.68 | $-92.43 | $-92.59 | $-153.94 |
| EPS Diluted | $-22.15 | $-17.89 | $-34.68 | $-9.95 | $-13.34 | $-22.16 | $-53.95 | $17.38 | $-31.59 | $-66.07 | $245.34 | $-68.59 | $-56.34 | $-62.93 | $-76.93 | $-72.26 | $-75.68 | $-92.43 | $-92.59 | $-153.94 |
| Weighted Average Shares Outstanding | 285.00K | 285.00K | 285.00K | 343.37K | 442.46K | 285.89K | 147.32K | 159.60K | 146.96K | 115.69K | 114.17K | 112.21K | 111.32K | 111.18K | 103.10K | 100.42K | 93.20K | 73.47K | 73.47K | 74.32K |
| Weighted Average Shares Outstanding Diluted | 285.00K | 285.00K | 285.00K | 343.37K | 442.46K | 285.89K | 147.32K | 159.60K | 146.96K | 115.69K | 114.17K | 112.21K | 111.32K | 111.18K | 103.10K | 100.42K | 93.20K | 73.47K | 73.47K | 74.32K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $8.71M | $16.90M | $22.64M | $45.04M | $39.98M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $8.71M | $16.90M | $22.64M | $45.04M | $39.98M |
| Net Receivables | $- | $- | $2.50M | $3.66M | $2.37M |
| Inventory | $- | $- | $1.57M | $3.08M | $4.78M |
| Other Current Assets | $1.95M | $2.16M | $2.31M | $3.86M | $4.92M |
| Total Current Assets | $10.66M | $19.07M | $27.45M | $52.57M | $47.26M |
| Property Plant Equipment Net | $4.93M | $5.78M | $6.76M | $3.96M | $5.54M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $-6.76M | $68.00K | $746.00K |
| Total Non-Current Assets | $4.93M | $5.78M | $6.76M | $4.03M | $6.28M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $15.59M | $24.84M | $34.22M | $56.60M | $53.55M |
| Account Payables | $- | $3.98M | $3.50M | $3.46M | $5.58M |
| Short Term Debt | $- | $- | $2.00M | $11.67M | $5.00M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-3.50M | $-3.46M | $-5.58M |
| Other Current Liabilities | $6.21M | $3.24M | $3.21M | $19.63M | $3.96M |
| Total Current Liabilities | $6.21M | $7.22M | $8.71M | $34.76M | $14.54M |
| Long Term Debt | $4.63M | $5.40M | $7.54M | $5.05M | $22.41M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $15.58M | $- |
| Total Non-Current Liabilities | $4.63M | $5.40M | $7.54M | $20.63M | $22.41M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $10.84M | $12.62M | $16.24M | $55.38M | $36.95M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $84.00K | $61.00K | $48.00K | $47.00K | $46.00K |
| Retained Earnings | $-247.58M | $-223.45M | $-206.04M | $-214.06M | $-185.61M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $252.25M | $235.61M | $223.96M | $215.23M | $202.15M |
| Total Stockholders Equity | $4.75M | $12.22M | $17.97M | $1.22M | $16.59M |
| Total Equity | $4.75M | $12.22M | $17.97M | $1.22M | $16.59M |
| Total Liabilities and Stockholders Equity | $15.59M | $24.84M | $34.22M | $56.60M | $53.55M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $15.59M | $24.84M | $34.22M | $56.60M | $53.55M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $4.63M | $5.40M | $9.54M | $16.71M | $27.41M |
| Net Debt | $-4.08M | $-11.51M | $-13.10M | $-28.33M | $-12.56M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $8.71M | $7.75M | $8.07M | $10.25M | $16.90M | $19.11M | $21.01M | $25.33M | $22.64M | $22.15M | $29.43M | $34.99M | $45.04M | $52.12M | $60.39M | $57.52M | $39.98M | $24.94M | $7.60M | $12.26M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $8.71M | $7.75M | $8.07M | $10.25M | $16.90M | $19.11M | $21.01M | $25.33M | $22.64M | $22.15M | $29.43M | $34.99M | $45.04M | $52.12M | $60.39M | $57.52M | $39.98M | $24.94M | $7.60M | $12.26M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $2.50M | $- | $- | $3.11M | $3.66M | $3.10M | $3.11M | $2.42M | $2.37M | $1.46M | $288.00K | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $1.57M | $- | $- | $2.69M | $3.08M | $3.65M | $2.19M | $2.82M | $4.78M | $4.04M | $2.50M | $- |
| Other Current Assets | $1.95M | $2.26M | $1.51M | $1.82M | $2.16M | $2.02M | $1.67M | $3.16M | $2.31M | $2.47M | $1.97M | $3.57M | $3.86M | $3.66M | $2.26M | $2.90M | $4.92M | $4.25M | $2.60M | $2.57M |
| Total Current Assets | $10.66M | $10.01M | $9.58M | $12.07M | $19.07M | $21.13M | $22.68M | $28.48M | $27.45M | $24.62M | $31.40M | $41.67M | $52.57M | $58.87M | $65.77M | $62.85M | $47.26M | $30.65M | $10.49M | $14.82M |
| Property Plant Equipment Net | $4.93M | $5.13M | $5.34M | $5.55M | $5.78M | $6.00M | $6.23M | $6.48M | $6.76M | $7.08M | $7.40M | $3.44M | $3.96M | $4.39M | $4.96M | $5.16M | $5.54M | $6.01M | $6.57M | $7.13M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $-1 | $- | $- | $- | $-6.23M | $-6.48M | $-6.76M | $-7.08M | $- | $68.00K | $68.00K | $746.00K | $746.00K | $746.00K | $746.00K | $757.00K | $1.45M | $3.29M |
| Total Non-Current Assets | $4.93M | $5.13M | $5.34M | $5.55M | $5.78M | $6.00M | $6.23M | $6.48M | $6.76M | $7.08M | $7.40M | $3.51M | $4.03M | $5.13M | $5.71M | $5.90M | $6.28M | $6.77M | $8.02M | $10.42M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $15.59M | $15.15M | $14.92M | $17.63M | $24.84M | $27.13M | $28.91M | $34.97M | $34.22M | $31.70M | $38.80M | $45.18M | $56.60M | $64.00M | $71.47M | $68.75M | $53.55M | $37.42M | $18.51M | $25.24M |
| Account Payables | $- | $3.53M | $3.74M | $3.72M | $3.98M | $4.00M | $4.87M | $4.13M | $3.50M | $3.24M | $3.27M | $3.91M | $3.46M | $3.69M | $5.20M | $5.35M | $5.58M | $3.91M | $4.66M | $4.70M |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $2.00M | $2.00M | $2.00M | $2.00M | $11.67M | $11.17M | $10.67M | $10.17M | $5.00M | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $-3.50M | $- | $1.70M | $1.04M | $-3.46M | $-3.69M | $-5.20M | $1.10M | $-5.58M | $- | $- | $- |
| Other Current Liabilities | $6.21M | $2.35M | $1.68M | $2.58M | $3.24M | $2.84M | $2.04M | $1.66M | $3.21M | $2.54M | $1.73M | $17.95M | $19.63M | $17.53M | $15.00M | $13.82M | $3.96M | $3.51M | $2.34M | $2.29M |
| Total Current Liabilities | $6.21M | $5.88M | $5.42M | $6.30M | $7.22M | $6.84M | $6.91M | $5.80M | $8.71M | $7.79M | $7.00M | $23.86M | $34.76M | $32.38M | $30.86M | $29.34M | $14.54M | $7.42M | $7.00M | $6.99M |
| Long Term Debt | $4.63M | $4.83M | $5.03M | $5.21M | $5.40M | $5.58M | $5.75M | $5.92M | $7.54M | $8.15M | $8.75M | $3.87M | $5.05M | $5.62M | $6.19M | $6.73M | $22.41M | $27.80M | $2.86M | $3.10M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $14.00K | $14.00K | $14.00K | $- | $- | $- | $- | $- | $- | $- | $23.34M | $15.58M | $18.71M | $20.54M | $22.17M | $- | $- | $- | $- |
| Total Non-Current Liabilities | $4.63M | $4.84M | $5.04M | $5.23M | $5.40M | $5.58M | $5.75M | $5.92M | $7.54M | $8.15M | $8.75M | $27.21M | $20.63M | $24.33M | $26.73M | $28.91M | $22.41M | $27.80M | $2.86M | $3.10M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $10.84M | $10.73M | $10.46M | $11.53M | $12.62M | $12.41M | $12.66M | $11.71M | $16.24M | $15.93M | $15.75M | $51.07M | $55.38M | $56.71M | $57.59M | $58.25M | $36.95M | $35.22M | $9.86M | $10.09M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $84.00K | $82.00K | $69.00K | $66.00K | $61.00K | $56.00K | $49.00K | $49.00K | $48.00K | $47.00K | $47.00K | $47.00K | $47.00K | $47.00K | $47.00K | $46.00K | $46.00K | $45.00K | $45.00K | $45.00K |
| Retained Earnings | $-247.58M | $-241.26M | $-236.16M | $-230.28M | $-223.45M | $-217.54M | $-211.21M | $-203.26M | $-206.04M | $-201.39M | $-193.75M | $-221.76M | $-214.06M | $-207.79M | $-200.79M | $-192.86M | $-185.61M | $-178.55M | $-171.76M | $-164.96M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $-0 | $- | $- | $0 | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $252.25M | $245.60M | $240.56M | $236.32M | $235.61M | $232.21M | $227.41M | $226.47M | $223.96M | $217.11M | $216.75M | $215.83M | $215.23M | $215.04M | $214.63M | $203.32M | $202.15M | $180.71M | $180.37M | $180.07M |
| Total Stockholders Equity | $4.75M | $4.42M | $4.46M | $6.10M | $12.22M | $14.72M | $16.25M | $23.26M | $17.97M | $15.76M | $23.05M | $-5.88M | $1.22M | $7.29M | $13.88M | $10.50M | $16.59M | $2.20M | $8.65M | $15.15M |
| Total Equity | $4.75M | $4.42M | $4.46M | $6.10M | $12.22M | $14.72M | $16.25M | $23.26M | $17.97M | $15.76M | $23.05M | $-5.88M | $1.22M | $7.29M | $13.88M | $10.50M | $16.59M | $2.20M | $8.65M | $15.15M |
| Total Liabilities and Stockholders Equity | $15.59M | $15.15M | $14.92M | $17.63M | $24.84M | $27.13M | $28.91M | $34.97M | $34.22M | $31.70M | $38.80M | $45.18M | $56.60M | $64.00M | $71.47M | $68.75M | $53.55M | $37.42M | $18.51M | $25.24M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $15.59M | $15.15M | $14.92M | $17.63M | $24.84M | $27.13M | $28.91M | $34.97M | $34.22M | $31.70M | $38.80M | $45.18M | $56.60M | $64.00M | $71.47M | $68.75M | $53.55M | $37.42M | $18.51M | $25.24M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $4.63M | $4.83M | $5.03M | $5.21M | $5.40M | $5.58M | $5.75M | $5.92M | $9.54M | $10.15M | $10.75M | $5.87M | $16.71M | $16.79M | $16.86M | $16.90M | $27.41M | $27.80M | $2.86M | $3.10M |
| Net Debt | $-4.08M | $-2.92M | $-3.04M | $-5.04M | $-11.51M | $-13.54M | $-15.26M | $-19.41M | $-13.10M | $-12.00M | $-18.68M | $-29.12M | $-28.33M | $-35.33M | $-43.53M | $-40.62M | $-12.56M | $2.86M | $-4.74M | $-9.16M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-24.13M | $-17.41M | $8.03M | $-28.46M | $-17.75M |
| Depreciation and Amortization | $352.00K | $567.00K | $901.00K | $1.14M | $1.41M |
| Deferred Income Tax | $- | $- | $- | $4.00K | $-12.23M |
| Stock Based Compensation | $1.07M | $2.19M | $1.80M | $1.64M | $1.25M |
| Change in Working Capital | $-1.08M | $2.91M | $2.14M | $-2.65M | $-2.41M |
| Accounts Receivables | $- | $2.50M | $1.16M | $-1.29M | $-2.37M |
| Inventory | $- | $- | $-1.16M | $1.29M | $-1.05M |
| Accounts Payables | $-1.02M | $518.00K | $-394.00K | $-1.92M | $-702.00K |
| Other Working Capital | $-59.00K | $-107.00K | $2.54M | $-740.00K | $1.72M |
| Other Non Cash Items | $- | $10.00K | $-33.90M | $6.64M | $411.00K |
| Net Cash Provided by Operating Activities | $-23.79M | $-11.73M | $-21.02M | $-21.68M | $-29.32M |
| Investments in Property Plant and Equipment | $- | $- | $-29.00K | $-713.00K | $-88.00K |
| Acquisitions Net | $- | $- | $- | $- | $28.12M |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $28.12M |
| Net Cash Used for Investing Activities | $- | $- | $-29.00K | $-713.00K | $28.03M |
| Debt Repayment | $- | $-3.47M | $-12.27M | $-10.55M | $2.63M |
| Common Stock Issued | $10.04M | $6.43M | $6.93M | $10.23M | $21.26M |
| Common Stock Repurchased | $- | $- | $- | $- | $-11.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.56M | $3.04M | $2.72M | $26.48M | $21.25M |
| Net Cash Used Provided by Financing Activities | $15.60M | $6.00M | $-2.62M | $26.16M | $23.87M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-8.19M | $-5.73M | $-23.67M | $3.77M | $22.59M |
| Cash at End of Period | $8.71M | $16.90M | $22.64M | $46.30M | $42.53M |
| Cash at Beginning of Period | $16.90M | $22.64M | $46.30M | $42.53M | $19.95M |
| Operating Cash Flow | $-23.79M | $-11.73M | $-21.02M | $-21.68M | $-29.32M |
| Capital Expenditure | $- | $- | $-29.00K | $-713.00K | $-88.00K |
| Free Cash Flow | $-23.79M | $-11.73M | $-21.05M | $-22.39M | $-29.41M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-6.31M | $-5.10M | $-5.88M | $-6.83M | $-6.20M | $-6.33M | $-7.95M | $2.77M | $-4.64M | $-7.64M | $28.01M | $-7.70M | $-6.27M | $-7.00M | $-7.93M | $-7.26M | $-7.05M | $-6.79M | $-6.80M | $2.90M |
| Depreciation and Amortization | $71.00K | $84.00K | $91.00K | $106.00K | $116.00K | $123.00K | $150.00K | $178.00K | $161.00K | $222.00K | $276.00K | $242.00K | $260.00K | $296.00K | $299.00K | $289.00K | $342.00K | $300.00K | $309.00K | $455.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-201.00K | $-778.00K | $349.00K | $- | $- | $- | $- | $- | $- | $-1.00K | $- | $5.00K | $- | $- | $- | $-12.23M |
| Stock Based Compensation | $-72.00K | $149.00K | $273.00K | $719.00K | $358.00K | $455.00K | $465.00K | $915.00K | $357.00K | $359.00K | $485.00K | $601.00K | $178.00K | $319.00K | $572.00K | $574.00K | $198.00K | $343.00K | $301.00K | $413.00K |
| Change in Working Capital | $554.00K | $1.28M | $-634.00K | $-642.00K | $176.00K | $-485.00K | $2.53M | $690.00K | $-1.84M | $195.00K | $3.74M | $50.00K | $-301.00K | $-892.00K | $-49.00K | $-1.41M | $585.00K | $-1.71M | $1.56M | $-2.84M |
| Accounts Receivables | $- | $- | $- | $- | $-2.50M | $- | $- | $2.50M | $-2.50M | $- | $3.11M | $550.00K | $52.00K | $14.00K | $-689.00K | $-52.00K | $-906.00K | $-1.46M | $-288.00K | $- |
| Inventory | $- | $- | $- | $- | $1.81M | $- | $- | $-1.81M | $2.50M | $- | $- | $- | $-52.00K | $- | $- | $-32.76M | $-33.36M | $-23.90M | $- | $- |
| Accounts Payables | $324.00K | $1.80M | $-879.00K | $-926.00K | $389.00K | $-76.00K | $1.11M | $-909.00K | $989.00K | $862.00K | $-1.45M | $-798.00K | $-220.00K | $457.00K | $-42.00K | $-2.11M | $2.12M | $415.00K | $9.00K | $-3.25M |
| Other Working Capital | $230.00K | $-529.00K | $245.00K | $284.00K | $-213.00K | $-409.00K | $1.42M | $909.00K | $-2.83M | $-667.00K | $2.07M | $848.00K | $-81.00K | $-1.35M | $-7.00K | $33.51M | $32.73M | $23.24M | $1.55M | $405.00K |
| Other Non Cash Items | $- | $-1.63M | $1.33M | $1.86M | $494.00K | $778.00K | $-349.00K | $10.00K | $24.00K | $-28.00K | $-35.58M | $1.69M | $2.25M | $2.03M | $2.06M | $297.00K | $-195.00K | $469.00K | $9.00K | $137.00K |
| Net Cash Provided by Operating Activities | $-5.76M | $-5.22M | $-6.15M | $-6.65M | $-5.25M | $-6.24M | $-4.80M | $4.57M | $-5.94M | $-6.90M | $-3.07M | $-5.12M | $-3.88M | $-5.24M | $-5.05M | $-7.50M | $-6.12M | $-7.39M | $-4.63M | $-11.18M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $-4.00K | $-25.00K | $- | $-118.00K | $-13.00K | $-391.00K | $-191.00K | $-88.00K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-28.12M | $- | $- | $28.12M |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $28.12M | $28.12M | $- | $28.12M |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $-4.00K | $-25.00K | $- | $-118.00K | $-13.00K | $-391.00K | $-191.00K | $-88.00K | $28.12M | $- | $28.12M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $-3.47M | $-500.00K | $-500.00K | $-500.00K | $-10.77M | $- | $- | $- | $-10.55M | $- | $- | $- | $-22.10M |
| Common Stock Issued | $1.16M | $4.91M | $3.97M | $- | $3.15M | $1.20M | $481.00K | $1.60M | $6.50M | $- | $436.00K | $- | $20.00K | $89.00K | $10.74M | $592.00K | $23.00K | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.00K | $10.23M | $- | $- | $- | $-11.00K | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-8.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.56M | $- | $-1.00K | $-3.00K | $-100.00K | $3.15M | $- | $-8.00K | $6.50M | $- | $-3.11M | $5.83M | $-3.08M | $-3.11M | $8.32M | $34.49M | $21.25M | $24.73M | $- | $- |
| Net Cash Used Provided by Financing Activities | $6.72M | $4.91M | $3.97M | $-3.00K | $3.05M | $4.34M | $481.00K | $-1.87M | $6.00M | $-500.00K | $-3.18M | $-4.94M | $-3.08M | $-3.02M | $8.32M | $23.94M | $21.25M | $24.73M | $- | $-22.10M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $25.00K | $- | $- | $- | $- | $- | $- | $- | $- | $-28.12M | $- | $- |
| Net Change in Cash | $961.00K | $-313.00K | $-2.18M | $-6.65M | $-2.21M | $-1.90M | $-4.32M | $2.69M | $59.00K | $-7.40M | $-6.27M | $-10.05M | $-7.07M | $-8.28M | $2.87M | $16.25M | $15.04M | $17.34M | $-4.63M | $-5.16M |
| Cash at End of Period | $8.71M | $7.75M | $8.07M | $10.25M | $16.90M | $19.11M | $21.01M | $25.33M | $22.64M | $22.58M | $29.98M | $36.25M | $46.30M | $53.38M | $61.65M | $58.78M | $42.53M | $27.50M | $10.15M | $14.79M |
| Cash at Beginning of Period | $7.75M | $8.07M | $10.25M | $16.90M | $19.11M | $21.01M | $25.33M | $22.64M | $22.58M | $29.98M | $36.25M | $46.30M | $53.38M | $61.65M | $58.78M | $42.53M | $27.50M | $10.15M | $14.79M | $19.95M |
| Operating Cash Flow | $-5.76M | $-5.22M | $-6.15M | $-6.65M | $-5.25M | $-6.24M | $-4.80M | $4.57M | $-5.94M | $-6.90M | $-3.07M | $-5.12M | $-3.88M | $-5.24M | $-5.05M | $-7.50M | $-6.12M | $-7.39M | $-4.63M | $-11.18M |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $-4.00K | $-25.00K | $- | $-118.00K | $-13.00K | $-391.00K | $-191.00K | $-88.00K | $- | $- | $- |
| Free Cash Flow | $-5.76M | $-5.22M | $-6.15M | $-6.65M | $-5.25M | $-6.24M | $-4.80M | $4.57M | $-5.96M | $-6.90M | $-3.10M | $-5.12M | $-4.00M | $-5.25M | $-5.44M | $-7.70M | $-6.21M | $-7.39M | $-4.63M | $-11.18M |
Aptevo Therapeutics Stock Forecast
Analyst ratings, price targets, and earnings estimates for APVO.
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
Aptevo Therapeutics Dividends
Explore Aptevo Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Kronos Bio, Inc.
KRON
|
$55.25M | $0.92 | $-1.95 | $-0.64 | $0.45 |
Cyclerion Therapeutics, Inc.
CYCN
|
$6.69M | $2.47 | $-1.21 | $-2.65 | $0.92 |
Larimar Therapeutics, Inc.
LRMR
|
$166.54M | $2.61 | $-0.84 | $-5.41 | $2.44 |
Addex Therapeutics Ltd
ADXN
|
$5.82M | $7.10 | $-0.14 | $-0.32 | $2.98 |
Achilles Therapeutics plc
ACHL
|
$58.36M | $1.42 | $-1.74 | $-0.51 | $0.25 |
|
$- | $ | $ | $ | $ |
Nutriband Inc.
NTRB
|
$67.97M | $6.12 | $-0.69 | $-3.78 | $3.22 |
Quoin Pharmaceuticals, Ltd.
QNRX
|
$1.49M | $0.30 | $-1911.50 | $0.00 | $0.00 |
Longeveron Inc.
LGVN
|
$24.53M | $1.64 | $-0.17 | $-10.19 | $7.44 |
RenovoRx, Inc.
RNXT
|
$36.28M | $1.02 | $-0.99 | $-2.30 | $-7.86 |
Virax Biolabs Group Limited
VRAX
|
$5.60M | $1.29 | $-3.36 | $-0.22 | $0.27 |
Passage Bio, Inc.
PASG
|
$24.36M | $0.39 | $-1.07 | $-0.53 | $0.56 |
Magenta Therapeutics, Inc.
MGTA
|
$42.44M | $0.70 | $-23.05 | $-0.02 | $0.01 |
TRACON Pharmaceuticals, Inc.
TCON
|
$109.72K | $0.03 | $-2.20 | $-1.59 | $-7.06 |
Invivyd, Inc.
IVVD
|
$97.14M | $0.81 | $-1.81 | $-2.17 | $2.43 |
Avenue Therapeutics, Inc.
ATXI
|
$1.59M | $0.77 | $-73.60 | $-0.16 | $1.08 |
Hoth Therapeutics, Inc.
HOTH
|
$14.33M | $1.09 | $-2.30 | $-0.63 | $0.56 |
Revelation Biosciences, Inc.
REVB
|
$2.96M | $3.27 | $-8768.31 | $0.00 | $0.00 |
NeuroBo Pharmaceuticals, Inc.
NRBO
|
$20.33M | $2.36 | $ | $ | $ |
Related Metrics
Explore detailed financial metrics and analysis for APVO.